An Overview of Research in the Field of Human Papilloma Virus (HPV) in Iran: a Systematic Review
Men's Health Journal,
Vol. 3 No. 1 (2019),
13 Farvardin 2019
,
Page e20
https://doi.org/10.22037/mhj.v3i1.33127
Abstract
Introduction: Human Papilloma Virus (HPV) has many different epidemiological, social and political aspects. The aim of this study was to determine the research priorities according to the necessary aspects of HPV in Iran. Methods: The national and international databases were searched to obtain the published articles regarding HPV in Iran. All Epidemiologic studies were included in this review to assess research priorities. Results: Of 148 studies involving 14,661 participants, the most studies were conducted in Tehran (44.75%) province. Measuring prevalence of HPV (n=63, 42.5%), diagnosis of HPV by molecular techniques (n=52, 35.1%), Knowledge, Attitude and Practice studies (KAP) (n=13, 8.7%), vaccine efficacy (n=8, 5.4%), cost and cost effectiveness analysis (n=4, 2.7%), co-infection of HPV and sexually transmitted diseases (n=5, 3.3%) were the frequent aims of the included studies. Sixty percent (n=57) of the studies were conducted in clinical patients including patients with cervical cancer (n=30, 52.6%), patients with prostate cancer/Benign Prostate Hyperplasia (n=6, 10.5%), and patients with Esophageal carcinoma (n=5, 8.7%). Conclusion: According to our results, the high-risk groups such as female sex workers, injecting drug users and prisoners are in priority for research in the field of HPV. Despite ample epidemiologic studies on prevalence and association of HPV with specific cancers, evidence towards effectiveness and cost-benefits of HPV vaccination is required to prevent the infection and its complicated clinical consequences.
How to Cite
References
Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. bmj. 2019;365.
Eftekhaar NS, Niya MHK, Izadi F, Teaghinezhad-S S, Keyvani H. Human papillomavirus (HPV) genotype distribution in patients with recurrent respiratory papillomatosis (RRP) in Iran. Asian Pacific Journal of Cancer Prevention: APJCP. 2017;18(7):1973.
Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males. Cochrane database of systematic reviews. 2019(11).
Sultana F, Winch K, Saville M, Brotherton JM. Is the positive predictive value of high‐grade cytology in predicting high‐grade cervical disease falling due to HPV vaccination? International journal of cancer. 2019;144(12):2964-71.
Aghakhani A, Mamishi S, Sabeti S, Bidari‑Zerehpoosh F, Banifazl M, Bavand A, et al. Gender and age‑specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran. Med Microbiol Immunol. 2017;206:105-10. DOI 10.1007/s00430-016-0487-5.
Bouvard V, Baan R, Straif K, al e. A review of human carcinogens-Part B: biological agents. . Lancet Oncol. 2009;10:321-2.
Doorbar J, Quint W, Banks L, al e. The biology and life-cycle of human papillomaviruses. . Vaccine. 2012;30:55-70.
Rodriguez AC, Schiffman M, Herrero R, al e. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102:315-24.
Bae JM, Kim EH. Human papillomavirus infection and risk of breast cancer: a meta-analysis of case-control studies. Infect Agent Cancer,. 2016;11(14).
Karimi M, Khodabandehloo M, Nikkhoo B, Ghaderi E. No Significant Association between Human Papillomavirus and Breast Cancer, Sanandaj, Iran. Asian Pac J Cancer Prev. 2016;17(10):4741-5.
Jalilvand S, Shoja Z, Hamkar R. Human Papillomavirus Burden in Different Cancers in Iran: a Systematic Assessment. Asian Pac J Cancer Prev. 2014;15(17):7029-35.
Jamdar F, Farzaneh F, Navidpour F, Younesi S, Balvayeh P, Hosseini M, et al. Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing. Infectious Agents and Cancer 2018;13(6).
Mou X, Chen L, Liu F, Shen Y, Wang H, Li Y, et al. Low prevalence of human papillomavirus (HPV) in Chinese patients with breast cancer. J Int Med Res 2011;39:1636-44.
Haghshenas MR, Mousavi T, Moosazadeh M, Afshari M. Human papillomavirus and breast cancer in Iran: a meta- analysis. Iran J Basic Med Sci 2016;19:231-7.
Newman L, Rowley J, Vander-Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. . PLoS ONE. 2015;10(12):e0143304.
Gottlieb SL, Low N, Newman LM, Bolan G, Kamb M, Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. . Vaccine. 2014;32(14):1527–35.
Shahesmaeili A, Karamouzian M, Shokoohi M, Kamali K, Fahimfar N, Nadji A, et al. Symptom‑Based Versus Laboratory‑Based Diagnosis of Five Sexually Transmitted Infections in Female Sex Workers in Iran. AIDS and Behavior. 2018:doi.org/10.1007/s10461-018-2130-5.
Yaghoubi M, Nojomi M, Vaezi A, Erfani V, Mahmoudi S, Ezoji K, et al. Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-GirlsinIran. Value In Health Regional Issues 2018;15:112-9.
Pourkazemi A, Fakour F, Ghorbani S. Knowledge and attitudes of medical students toward human papilloma virus in Rasht. . J Guilan Univ of Med Sci. 2016;25:1–10.
Klug SJ, Hukelmann M, Blettner M. Knowledge about infection with human papillomavirus: a systematic review. . Prev Med 2008;46:87–98.
Taebi M, Riazi H, Keshavarz Z, Afrakhteh M. Knowledge and Attitude Toward Human Papillomavirus and HPV Vaccination in Iranian Population: A Systematic Review. Asian Pac J Cancer Prev. 2019;20(7):1945-9. doi: 10.31557/APJCP.2019.20.7.1945.
- Abstract Viewed: 163 times
- pdf Downloaded: 109 times